Shenzhen SiBiono GeneTech Co.,Ltd
11
0
0
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 11 trials
27%
3 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study
Role: collaborator
p53 Gene Therapy in Treatment of Diabetes Concurrent With Hepatocellular Carcinoma
Role: lead
Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma
Role: lead
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Role: lead
Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural Effusion
Role: lead
P53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable Locally Advanced Head and Neck Cancer
Role: lead
Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma
Role: lead
Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma
Role: lead
rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors
Role: lead
p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage
Role: lead
rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors
Role: lead
All 11 trials loaded